Cyclacel Pharmaceuticals Stock Performance
| CYCC Stock | USD 0.35 0.01 2.94% |
The firm shows a Beta (market volatility) of 0.0476, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cyclacel Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cyclacel Pharmaceuticals is expected to be smaller as well. At this point, Cyclacel Pharmaceuticals has a negative expected return of -1.39%. Please make sure to confirm Cyclacel Pharmaceuticals' potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Cyclacel Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 18.3 M | |
| Free Cash Flow | -16.1 M |
Cyclacel |
Cyclacel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 104.00 in Cyclacel Pharmaceuticals on August 29, 2024 and sell it today you would lose (69.00) from holding Cyclacel Pharmaceuticals or give up 66.35% of portfolio value over 90 days. Cyclacel Pharmaceuticals is currently does not generate positive expected returns and assumes 7.6482% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Cyclacel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cyclacel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclacel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyclacel Pharmaceuticals, and traders can use it to determine the average amount a Cyclacel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1814
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYCC |
Estimated Market Risk
| 7.65 actual daily | 68 68% of assets are less volatile |
Expected Return
| -1.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cyclacel Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclacel Pharmaceuticals by adding Cyclacel Pharmaceuticals to a well-diversified portfolio.
Cyclacel Pharmaceuticals Fundamentals Growth
Cyclacel Stock prices reflect investors' perceptions of the future prospects and financial health of Cyclacel Pharmaceuticals, and Cyclacel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyclacel Stock performance.
| Return On Equity | -5.71 | ||||
| Return On Asset | -1.03 | ||||
| Operating Margin | (911.00) % | ||||
| Current Valuation | (819.2 K) | ||||
| Shares Outstanding | 6.29 M | ||||
| Price To Earning | (0.40) X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 27.98 X | ||||
| Revenue | 420 K | ||||
| EBITDA | (25.42 M) | ||||
| Cash And Equivalents | 29.08 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 37 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (16.11 M) | ||||
| Earnings Per Share | (26.48) X | ||||
| Total Asset | 8.8 M | ||||
| Retained Earnings | (428.28 M) | ||||
| Current Asset | 24.57 M | ||||
| Current Liabilities | 5.75 M | ||||
About Cyclacel Pharmaceuticals Performance
By analyzing Cyclacel Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Cyclacel Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cyclacel Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cyclacel Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Things to note about Cyclacel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cyclacel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyclacel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyclacel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cyclacel Pharmaceuticals has high historical volatility and very poor performance | |
| Cyclacel Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cyclacel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with loss before overhead, payroll, taxes, and interest of (455 K). | |
| Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Cyclacel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyclacel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cyclacel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyclacel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyclacel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyclacel Pharmaceuticals' stock. These opinions can provide insight into Cyclacel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |